// App-Quantinova.ai

21602 : Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Researchers

Presenter

  • Kenneth W Mahaffey

Principal Investigators

  • Bruce Neal

  • Vlado Perkovic

  • Dick de Zeeuw

  • Greg Fulcher

  • Ngozi Erondu

  • Wayne Shaw

  • Tao Sun

  • Mehul Desai

  • David R Matthews

Medical Centers

  • Dept of Medicine, Stanford Cntr for Clinical Rsch, Stanford Univ Sch of Medicine, Stanford, CA

  • Food Policy Div, The George Institute for Global Health, Sydney, Australia

  • George Inst Global Health, Sydney NSW, Australia

  • Department of clinical pharmacy and pharmacology University of Groningen University Medical Center Groningen Groningen Netherlands

  • Royal North Shore Hospital/ University of Sydney, St Leonards, Australia

  • SH CVM Metabolics, Janssen Rsch & Development, LLC, Raritan, NJ

  • SH CVM Metabolics, Janssen Rsch & Development, LLC, Raritan, NJ

  • Clinical Biostats, Janssen Rsch & Development, LLC, Raritan, NJ

  • Oxford Centre for Diabetes, Endocrinology and Metabolism and Harris Manchester College, University of Oxford, Oxford, United Kingdom

Locations

  • United States

  • Australia

  • Netherlands

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Canagliflozin

Outcome

  • N/A

Study Design

  • Placebo Control

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved